Xu Jie Ying

Chairman en ZHEJIANG INT'L GROUP CO.,LTD. .

51 años

Health Technology

Consumer Services

Perfil

Xu Jie Ying is currently the Chairman at Zhejiang Int'l Group Co., Ltd.
and Zhejiang International Pharmaceutical Co., Ltd.
Prior to his current positions, he obtained an undergraduate degree from Shenyang Pharmaceutical University in 1995.

Cargos activos de Xu Jie Ying

Empresas	Cargo	Inicio
ZHEJIANG INT'L GROUP CO.,LTD.	Chairman	06/07/2022
Zhejiang International Pharmaceutical Co., Ltd. Zhejiang International Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Zhejiang Int' l Group Co., Ltd., Zhejiang International Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company that manufactures and distributes pharmaceutical products. The private company is based in Hangzhou, China. The company was founded in 1998. The CEO is Mi Yang. Zhejiang International Pharmaceutical Co. was acquired by Zhejiang Int'l Group Co., Ltd. on May 30, 2015 for $197.01 million.	Chairman	-

Todos los cargos activos de Xu Jie Ying

Formación de Xu Jie Ying.

Shenyang Pharmaceutical University

Undergraduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Xu Jie Ying.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
ZHEJIANG INT'L GROUP CO.,LTD.	Health Technology

Empresas privadas	1
Zhejiang International Pharmaceutical Co., Ltd. Zhejiang International Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Zhejiang Int' l Group Co., Ltd., Zhejiang International Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company that manufactures and distributes pharmaceutical products. The private company is based in Hangzhou, China. The company was founded in 1998. The CEO is Mi Yang. Zhejiang International Pharmaceutical Co. was acquired by Zhejiang Int'l Group Co., Ltd. on May 30, 2015 for $197.01 million.	Health Technology